Evidence map›Paper›PMID 39345100›Full record

ArticleFuture oncology (London, England)2024

Real-world results of first-line immunotherapy or targeted therapy for metastatic melanoma in Finland: a cohort study.

Kalle E Mattila, Leena Tiainen, Johanna Vikkula, Anna Kreutzman, Mia Engström-Risku, Kai Kysenius, Olivia Hölsä, Sari Hernesniemi, Päivikki Hemmilä, Anssi Pystynen and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kalle E MattilaDepartment of Oncology & Radiotherapy & Fican West Cancer Centre, University of Turku and Turku University Hospital, Turku, Finland.ORCID 0000-0002-9688-9187
Leena TiainenDepartment of Oncology, Tays Cancer Centre, Tampere University Hospital & Faculty of Medicine & Health Technology, Tampere University, Tampere, Finland.
Johanna VikkulaMedaffcon Oy, Espoo, Finland.
Anna KreutzmanNovartis Finland Oy, Espoo, Finland.
Mia Engström-RiskuNovartis Finland Oy, Espoo, Finland.
Kai KyseniusMedaffcon Oy, Espoo, Finland.
Olivia HölsäMedaffcon Oy, Espoo, Finland.
Sari HernesniemiNovartis Finland Oy, Espoo, Finland.
Päivikki HemmiläNovartis Finland Oy, Espoo, Finland.
Anssi PystynenNovartis Finland Oy, Espoo, Finland.
Siru MäkeläComprehensive Cancer Center, Helsinki University Hospital & University of Helsinki, Helsinki, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Brain NeoplasmsImmune Checkpoint InhibitorsLiver NeoplasmsMelanomaProtein Kinase InhibitorsSkin NeoplasmsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleFinlandFollow-Up StudiesHumansImmunotherapyMaleBRAF protein, humanImmune Checkpoint InhibitorsMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafBRAFbrain metastasisimmunotherapylactate dehydrogenaseliver metastasismelanomaoverall survivalreal-world evidencetargeted therapy

Identifiers

PMID39345100
PMCPMC11778799

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.